SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

311 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-23

Study Completion Date

2022-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment

NCT05119738

Sars-CoV-2 Infection

UNKNOWN

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

NCT04910295

Cancer Covid19

COMPLETED

Responses to COVID-19 Vaccination in Patients With Cancer

NCT04745377

Cancer

COMPLETED

Vaccination Against COVID-19 in Cancer

NCT04715438

Cancer

ACTIVE_NOT_RECRUITING NA

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

NCT05228275

COVID-19 Infection Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 311 participants, including 107 patients with solid tumor and 204 healthy volunteers who received 2 doses of CoronaVac were recruited from National Cancer Institute of Thailand between 2020-2021. Blood samples were collected after second dose of CoronaVac for 15 days and the neutralizing antibody (NAb) titers were detected using live-virus neutralization.SARS-CoV-2 antibody positivity was detected in 77 (72%) patients and 199 (97.5%) healthy volunteers. Antibody positivity rate was lowest (67.2%) in patients who received chemotherapy, followed by patients with post-treatment (74.2%) and patients who planned to start treatment (91.7%). Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, heterologous or otherwise, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Cancer patients and healthy volunteers will be compared for effectiveness of CoronaVac vaccine in parallel after 2 doses of vaccination for 15 days by neutralizing antibody test

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

All participants, including patients with solid tumor and healthy volunteers will be received 2 doses of CoronaVac at National Cancer Institute of Thailand between 2020-2021. Blood samples will be collected after second dose of Sinovac for 15 days and the neutralizing antibody (NAb) titers will be detected using live-virus neutralization

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers

Healthcare workers at National Cancer Institute

Group Type PLACEBO_COMPARATOR

CoronaVac vaccine

Intervention Type BIOLOGICAL

An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.

Cancer patients

Cancer patients were divided into 3 groups based on treatment status including

1. active cancer on treatment
2. Planned to start treatment
3. Post-treatment (\<6 months)

Group Type ACTIVE_COMPARATOR

CoronaVac vaccine

Intervention Type BIOLOGICAL

An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CoronaVac vaccine

An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sinovac

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female age at least 18 years
* Patients with a diagnosis of solid tumors
* Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure
* Willing and able to comply with the study procedures.
* Willing to receive a Coronavac vaccine (Sinovac).